Compare Pfizer Inc (PFE) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Target Corporation — how do they compare? Pfizer Inc trades at $24.89 (market cap $142.14B), while Target Corporation trades at $137.92 (market cap $63.40B). The key difference: Pfizer Inc is far larger — about 2.2× Target Corporation's market cap, and Pfizer Inc pays the higher dividend (6.9%). Which is the better fit depends on your goals.
| PFE | TGT | |
|---|---|---|
Market Cap | $142.14B | $63.40B |
Volume | 29,869,932 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $28.56 | $141.19 |
52-Week Low | $23.29 | $83.68 |
Enterprise Value | $192.80B | $78.70B |
Dividend Yield | 6.9% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.
Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.
Target Corporation (TGT) trades at $138.50, down 0.8% on the day, with a bullish technical outlook supported by moving averages. The company maintains stable revenue near $106.6 billion (2025) and has beaten earnings estimates for three consecutive quarters. Recent news highlights new product collaborations and institutional buying interest, while analyst consensus leans slightly bullish with a $138.21 price target.
Target's investment case balances solid fundamentals against margin pressures. Opportunities include consistent dividend payments and market share gains in retail, but risks involve competitive pressures and potential consumer spending slowdowns. The stock offers value with a P/E of 18.44 but requires monitoring of net income margin trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
